Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-09-26 14:00:15
2022 har vært et veldig aktivt år for Targovax og vår sektor, og vi inviterer
til et investormøte tirsdag 27. september, 2022. DNB vil gi en analytikers syn
på bioteknologimarkedet, etterfulgt av presentasjoner fra Targovax med fokus på
sirkulær RNA. Vi avslutter arrangementet med en mulighet for å snakke med
medlemmer av vårt lederteam i en uformell setting med mat og forfriskninger.
Targovax' lederteam vil presentere på norsk og er tilgjengelig for spørsmål
under det sosiale arrangementet.
Dato: Tirsdag 27. september
Tid: 17.00-19.00
Sted: Sentralen, Øvre Slottsgate 3, Oslo
· En analytikers syn på bioteknologimarkedet
· o Dr. Geir Hiller Holom, senior aksjeanalytiker i DNB Markets
· Targovax Business Oversikt
· o Dr. Erik Digman Wiklund, administrerende direktør i Targovax
· Sirkulær RNA (circRNA) - det mest nyskapende innen RNA-terapi, oppdaget i
Skandinavia
· o Dr. Thomas Hansen, VP Research i Targovax
Det blir uformell Q&A og servering av mat fra kl 17:45.
Lubor Gaal, finansdirektør og Andreas Storsve, VP Business Development, vil også
være til stede.
Påmelding sendes til
renate.birkeli@targovax.com (renate.birkeli@targovax.com?subject=P%C3%A5melding%
2
0investorm%C3%B8te&body=Hei%2C%20%0A%0AJeg%20vil%20gjerne%20registerer%20meg%20f
o
r%20investorm%C3%B8tet%20tirsdag%2027.%20september.%20)
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable
safety and tolerability profile.
Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. Following very
encouraging clinical data in several indications, both as monotherapy and in
combinations, ONCOS-102 is progressing into a randomized phase 2 trial in
melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Building on successful studies demonstrating clinical efficacy and providing
deep mechanistic insights, the Targovax platform is being expanded into delivery
of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy
program, with lead cancer vaccine candidate, TG01, due to enter the clinic in
the second half of 2022. This provides Targovax with a rich pipeline of
innovative future immunotherapy product candidates to follow ONCOS-102.